US Patent

US8324232 — 4-pyrimidinesulfamide derivative

Method of Use · Assigned to Actelion Pharmaceuticals Ltd · Expires 2029-09-21 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a process for preparing a compound useful as an endothelin receptor antagonist, specifically a 4-pyrimidinesulfamide derivative.

USPTO Abstract

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.

Drugs covered by this patent

Tryvio (APROCITENTAN) · Idorsia

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3878`	—	Tryvio

Patent Metadata

Patent number: US8324232
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-21
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.